氨甲环酸在有静脉血栓栓塞史关节置换患者中安全:一项配对结局研究
该回顾性研究纳入2000至2012年间1262例(1620膝/髋)有静脉血栓栓塞史行初次全髋或全膝关节置换的患者,258例(16%)使用静脉氨甲环酸,1362例(84%)未使用。术后90天静脉血栓栓塞复发率在氨甲环酸组为2.3%(6/258),未使用组为1.8%(25/1362),差异无统计学意义(P=.6);31例复发患者2:1配对后,静脉氨甲环酸与复发风险增加无关(比值比0.9;P=.9)。
要点
- 有静脉血栓栓塞史患者行初次全髋或全膝关节置换术后90天复发率低(2%)。
- 静脉氨甲环酸组复发率2.3%(6/258)对比未使用组1.8%(25/1362),P=.6,无显著差异。
- 配对分析中静脉氨甲环酸与复发风险增加无关(比值比0.9;P=.9)。
核心结论
- 有静脉血栓栓塞史的患者在接受现代全髋或全膝关节置换术后静脉血栓栓塞复发风险低(2%),使用静脉氨甲环酸未增加该风险。
研究设计与样本
- 回顾性综述2000至2012年间1262例(1620例次)有静脉血栓栓塞史行初次全髋或全膝关节置换的患者。
- 静脉氨甲环酸用于258例次(16%),未用于1362例次(84%);术后90天评估静脉血栓栓塞发生率。
- 发生复发性静脉血栓栓塞的患者按年龄(±5岁)、性别、体重指数(±5 kg/m2)、美国麻醉医师协会评分及化学预防类型与无复发患者进行2:1回顾性匹配。
主要发现
- 静脉血栓栓塞复发在氨甲环酸组为2.3%(6/258),未使用组为1.8%(25/1362),差异无统计学意义(P=.6)。
- 31例复发性静脉血栓栓塞患者与对照组2:1匹配后,静脉氨甲环酸与复发风险增加无关(比值比0.9;P=.9)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In contemporary total hip arthroplasties (THAs) and total knee arthroplasties (TKAs), intravenous tranexamic acid (IV TXA) has proved efficacious in decreasing blood loss and transfusion. Interested in expanding the use of IV TXA to patients with a prior venous thromboembolic event (VTE), we sought out to determine the risk of recurrent VTE with TXA administration during primary THA and TKA. METHODS: We retrospectively reviewed 1262 patients (1620 cases) with a history of VTE who underwent primary THA or TKA between 2000 and 2012. IV TXA was given in 258 (16%) of the cases and not given in 1362 (84%). VTE rates were evaluated at 90 days postoperatively. Given the rarity of recurrent VTEs, patients who experienced a recurrent VTE were 2:1 retrospectively matched against patients in the cohort with a history of VTE who did not experience a recurrent VTE using age (±5 years), sex, body mass index (±5 kg/m2), American Society of Anesthesiologist score, and type of chemoprophylaxis. RESULTS: VTE recurrence was not significantly greater in those who received TXA (2.3%; 6/258) compared to those who did not receive TXA (1.8%; 25/1362; P = .6). When the 31 patients who experienced a recurrent VTE were 2:1 matched to control patients, IV TXA was not associated with any increase in the risk of recurrent VTE (odds ratio, 0.9; P = .9). CONCLUSION: Patients with a history of VTE had a low risk of recurrent VTE (2%) after contemporary THA and TKA, and that rate was not increased with the use of IV TXA.
引用
- Sabbag OD, Abdel MP, Amundson AW, et al. Tranexamic Acid Was Safe in Arthroplasty Patients With a History of Venous Thromboembolism: A Matched Outcome Study. J Arthroplasty. 2017. PMID: 28262452. doi:10.1016/j.arth.2017.02.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。